Human hepatic and renal microsomes, Cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer

被引:93
作者
Stiborová, M
Frei, E
Hodek, P
Wiessler, M
Schmeiser, HH
机构
[1] Charles Univ Prague, Dept Biochem, Fac Sci, CS-12840 Prague 2, Czech Republic
[2] German Canc Res Ctr, Div Mol Toxicol, D-6900 Heidelberg, Germany
关键词
aristolochic acid; carcinogen; urothelial cancer; liver and kidney mwicrosomal enzymes; activation; DNA adduct; P-32; postlabeling;
D O I
10.1002/ijc.20564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, has been associated with the development of urothelial cancer in humans. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. Using the P-32 postlabeling assay, we examined the ability of microsomal samples from 8 human livers and from I human kidney to activate AAI, the major component of the plant extract AA, to metabolites forming adducts in DNA. Microsomes of both organs generated DNA adduct patterns reproducing those found in renal tissues from humans exposed to AA. 7-(deoxyadenosin-N (6)-yl)aristolactam 1, 7-(deoxyguanosin-N-2-yl)aristolactam I and 7-(deoxyadenosin-N-6-yl)arist lactam II were identified as AA-DNA adducts formed from AAI by all human hepatic and renal microsomes. To define the role of human microsomal enzymes in the activation of AAI, we investigated the modulation of AAI-DNA adduct formation by cofactors and selective inhibitors of microsomal reductases, cytochrome P450 (CYP) enzymes, NADPH:CYP reductase and NADH:cytochrome b(5) reductase. We also determined whether the activties of CYP and NADPH:CYP reductase in different human hepatic microsomal samples correlated with the levels of AAI-DNA adducts formed by the same microsomal samples. On the basis of these studies, we attribute most of the activation of AAI in human hepatic microsomes to CYPIA2. In contrast to human hepatic microsomes, in human renal microsomes NADPH:CYP reductase is more effective in AAI activation. In addition, prostaglandin H synthase is another enzyme activating AAI in renal microsomes. The results demonstrate for the first time the potential of microsomal enzymes in human liver and kidney to activate AAI by nitroreduction.
引用
收藏
页码:189 / 197
页数:9
相关论文
共 57 条
[1]  
Anzenbacher P, 1998, DRUG METAB DISPOS, V26, P56
[2]  
Arlt VM, 2003, CANCER RES, V63, P2752
[3]   Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene [J].
Arlt, VM ;
Wiessler, M ;
Schmeiser, HH .
CARCINOGENESIS, 2000, 21 (02) :235-242
[4]   Aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? [J].
Arlt, VM ;
Ferluga, D ;
Stiborova, M ;
Pfohl-Leszkowicz, A ;
Vukelic, M ;
Ceovic, S ;
Schmeiser, HH ;
Cosyns, JP .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (05) :500-502
[5]   Aristolochic acid as a probable human cancer hazard in herbal remedies: a review [J].
Arlt, VM ;
Stiborova, M ;
Schmeiser, HH .
MUTAGENESIS, 2002, 17 (04) :265-277
[6]   Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR [J].
Arlt, VM ;
Schmeiser, HH ;
Pfeifer, GP .
CARCINOGENESIS, 2001, 22 (01) :133-140
[7]   Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy [J].
Arlt, VM ;
Pfohl-Leszkowicz, A ;
Cosyns, JP ;
Schmeiser, HH .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2001, 494 (1-2) :143-150
[8]   P-32-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy [J].
Bieler, CA ;
Stiborova, M ;
Wiessler, M ;
Cosyns, JP ;
deStrihou, CV ;
Schmeiser, HH .
CARCINOGENESIS, 1997, 18 (05) :1063-1067
[9]  
Chae YH, 1999, CANCER RES, V59, P1473
[10]   Aristolochic acid and 'Chinese herbs nephropathy' - A review of the evidence to date [J].
Cosyns, JP .
DRUG SAFETY, 2003, 26 (01) :33-48